Astellas Pharma Inc.
ALPMF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3,544 | $505,794 | $459,294 | $517,408 |
| % Growth | -99.3% | 10.1% | -11.2% | – |
| Cost of Goods Sold | $935 | $94,829 | $76,858 | $98,523 |
| Gross Profit | $2,610 | $410,965 | $382,436 | $418,885 |
| % Margin | 73.6% | 81.3% | 83.3% | 81% |
| R&D Expenses | $484 | $71,698 | $76,229 | $79,092 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,398 | $196,997 | $211,316 | $225,305 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $47,623 | $31,371 | $230,679 |
| Operating Expenses | $1,882 | $316,318 | $318,916 | $535,076 |
| Operating Income | $728 | $94,647 | $63,520 | -$116,191 |
| % Margin | 20.5% | 18.7% | 13.8% | -22.5% |
| Other Income/Exp. Net | -$23 | -$4,231 | -$2,966 | -$2,168 |
| Pre-Tax Income | $704 | $90,416 | $60,554 | -$118,359 |
| Tax Expense | $169 | $21,994 | -$14,342 | -$20,699 |
| Net Income | $535 | $68,422 | $74,896 | -$97,660 |
| % Margin | 15.1% | 13.5% | 16.3% | -18.9% |
| EPS | 0.3 | 38.22 | 41.83 | -54.57 |
| % Growth | -99.2% | -8.6% | 176.7% | – |
| EPS Diluted | 0.3 | 38.11 | 41.19 | -54.57 |
| Weighted Avg Shares Out | 1,791 | 1,795 | 1,818 | 1,790 |
| Weighted Avg Shares Out Dil | 1,798 | 1,795 | 1,818 | 1,790 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $0 | $0 | $0 |
| Interest Expense | $18 | $4,231 | $2,967 | $2,167 |
| Depreciation & Amortization | $320 | $47,804 | $47,683 | $51,164 |
| EBITDA | $1,042 | $151,845 | $101,785 | $126,058 |
| % Margin | 29.4% | 30% | 22.2% | 24.4% |